文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

抑制大肠埃希菌黏附后血管内皮细胞渗漏:脓毒症体外模型研究

Inhibition of Vascular Endothelial Cell Leak Following Escherichia coli Attachment in an Experimental Model of Sepsis.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论体外实验显示西仑吉肽抑制大肠埃希菌外膜蛋白A与内皮整合素αVβ3结合,减轻内皮功能障碍,作者认为可能成为脓毒症早期新疗法。

该研究采用体外血流动力学灌注模型,将脓毒症患者分离的大肠埃希菌临床菌株与人血管内皮细胞共孵育,发现细菌外膜蛋白A直接结合内皮整合素αVβ3,导致紧密连接蛋白染色丢失、通透性改变及细胞凋亡。使用低浓度αVβ3拮抗剂西仑吉肽或外膜蛋白A缺陷菌株,可显著减轻感染后内皮功能障碍。作者认为,阻断该结合可能为脓毒症提供早期治疗新靶点,但尚需进一步研究。

要点

  • 脓毒症患者分离的大肠埃希菌临床菌株在静态和血流剪切条件下均可黏附于剪切的人内皮细胞。
  • 黏附依赖细菌外膜蛋白A与内皮整合素αVβ3直接结合,并导致紧密连接蛋白染色丢失、通透性改变和细胞凋亡。
  • 低浓度αVβ3拮抗剂西仑吉肽或外膜蛋白A缺陷菌株可显著减轻感染后内皮功能障碍。
  • 作者认为,西仑吉肽抑制大肠埃希菌与内皮αVβ3结合、防止内皮功能障碍,可能成为脓毒症的新型早期治疗。

适用人群与场景

  • 体外研究:人血管内皮细胞与脓毒症患者分离的大肠埃希菌临床菌株共孵育,在静态和血流动力学剪切条件下观察。

研究设计与关键结果

  • 研究类型:实验室研究,采用血流动力学灌注体外模型;地点为爱尔兰皇家外科医学院(Royal College of Surgeons in Ireland)和Beaumont医院研究实验室。
  • 脓毒症患者分离的大肠埃希菌临床菌株在静态和血流动力学剪切条件下均结合于剪切的人内皮细胞。
  • 结合依赖大肠埃希菌细胞膜蛋白外膜蛋白A直接附着于内皮细胞整合素αVβ3。
  • 附着导致内皮屏障完整性破坏,表现为紧密连接蛋白染色丢失、通透性改变,最终细胞凋亡死亡。
  • 使用低浓度αVβ3拮抗剂西仑吉肽或使用外膜蛋白A缺陷菌株,感染后内皮功能障碍显著减少。

证据类型、等级与局限

  • 证据类型:实验室体外研究(血流动力学灌注离体模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,西仑吉肽抑制大肠埃希菌与内皮细胞αVβ3结合、防止内皮功能障碍,可能作为脓毒症的新型早期治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: The vascular endothelium is a major target of sepsis-induced events, and endothelial activation accounts for much of the pathology of sepsis. Urinary tract infections and pneumonia caused by Escherichia coli are among of the most common infections causing sepsis in both community and hospital settings. Currently, there are no approved drugs on the market to treat the underlying pathophysiology of sepsis. The aim of this study is to elucidate the molecular mechanism by which E. coli induces endothelial injury as a result of attachment.

DESIGN: Laboratory research using a hemodynamic perfusion ex vivo model.

SETTING: Research Laboratories of Royal College of Surgeons in Ireland and Beaumont Hospital.

PATIENTS: Ex vivo human vascular endothelial cells.

INTERVENTIONS: Addition of αVβ3 antagonist, cilengitide.

MEASUREMENTS AND MAIN RESULTS: Clinical strains of E. coli isolated from patients with sepsis bound to sheared human endothelial cells under static and hemodynamic shear conditions. Binding was dependent on E. coli cell membrane protein outer membrane protein A attaching directly to endothelial cell integrin αVβ3. Attachment resulted in disturbances in endothelial barrier integrity, as determined by loss of tight junction protein staining, permeability changes, and ultimately cell death by apoptosis. Using a low concentration of the αVβ3 antagonist cilengitide or using a strain deficient in outer membrane protein A resulted in a significant reduction in endothelial dysfunction following infection.

CONCLUSIONS: Inhibition of E. coli binding to endothelial cell αVβ3 by cilengitide prevents endothelial dysfunction and may, therefore, present as a novel early therapeutic for the treatment of sepsis.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. McHale TM, Garciarena CD, Fagan RP, et al. Inhibition of Vascular Endothelial Cell Leak Following Escherichia coli Attachment in an Experimental Model of Sepsis. Crit Care Med. 2018. PMID: 29782355. doi:10.1097/CCM.0000000000003219

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。